EFM
E Fund Management Portfolio holdings
AUM
$2.1B
1-Year Return
23.31%
This Quarter Return
+21.94%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$1.2B
AUM Growth
+$128M
(+12%)
Cap. Flow
-$24.9M
Cap. Flow
% of AUM
-2.07%
Top 10 Holdings %
Top 10 Hldgs %
56.76%
Holding
362
New
28
Increased
88
Reduced
207
Closed
28
Top Buys
| 1 |
Tencent Music
TME
|
+$41.7M |
| 2 |
Yum China
YUMC
|
+$10.6M |
| 3 |
STAAR Surgical
STAA
|
+$8.25M |
| 4 |
Sea Limited
SE
|
+$7.13M |
| 5 |
Legend Biotech
LEGN
|
+$5.83M |
Top Sells
| 1 |
NIO
NIO
|
+$44.7M |
| 2 |
KE Holdings
BEKE
|
+$22M |
| 3 |
Kanzhun
BZ
|
+$10.1M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$10.1M |
| 5 |
Li Auto
LI
|
+$8.53M |
Sector Composition
| 1 | Consumer Discretionary | 36.91% |
| 2 | Technology | 25.51% |
| 3 | Communication Services | 14.94% |
| 4 | Healthcare | 9.44% |
| 5 | Real Estate | 3.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
Boeing
BA
$174B
| $205K | 0.02% |
+1,074
| New | +$205K |
|
302
Datadog
DDOG
$49B
| $204K | 0.02% |
2,775
-91
| -3% | -$6.69K |
|
303
Enanta Pharmaceuticals
ENTA
$193M
| $203K | 0.02% |
4,369
-12
| -0.3% | -$558 |
|
304
Prologis
PLD
$104B
| $200K | 0.02% |
+1,776
| New | +$200K |
|
|
SRNE
305
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $198K | 0.02% |
223,808
+22,818
| +11% | +$20.2K |
|
306
Cogent Biosciences
COGT
$1.79B
| $196K | 0.02% |
16,975
+2,585
| +18% | +$29.8K |
|
307
Coherus Oncology, Inc. Common Stock
CHRS
$157M
| $195K | 0.02% |
24,587
+6,114
| +33% | +$48.5K |
|
|
ICPT
308
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $172K | 0.01% |
13,932
-1,576
| -10% | -$19.5K |
|
309
Protagonist Therapeutics
PTGX
$3.63B
| $169K | 0.01% |
15,482
-8,366
| -35% | -$91.3K |
|
310
Ocugen
OCGN
$322M
| $168K | 0.01% |
129,498
-3,440
| -3% | -$4.46K |
|
311
ADMA Biologics
ADMA
$3.91B
| $161K | 0.01% |
41,376
+1,518
| +4% | +$5.91K |
|
312
Geron
GERN
$868M
| $161K | 0.01% |
66,662
+28,724
| +76% | +$69.4K |
|
|
EQRX
313
DELISTED
EQRx, Inc. Common Stock
EQRX
| $158K | 0.01% |
64,425
+24,197
| +60% | +$59.3K |
|
314
Myriad Genetics
MYGN
$649M
| $157K | 0.01% |
10,822
-961
| -8% | -$13.9K |
|
|
ALLK
315
DELISTED
Allakos
ALLK
| $141K | 0.01% |
+16,749
| New | +$141K |
|
316
Viatris
VTRS
$12.2B
| $137K | 0.01% |
12,294
-3,263
| -21% | -$36.4K |
|
317
Norwegian Cruise Line
NCLH
$11.5B
| $130K | 0.01% |
10,598
| – | – |
|
318
Kezar Life Sciences
KZR
$29.4M
| $129K | 0.01% |
1,827
+145
| +9% | +$10.2K |
|
319
Design Therapeutics
DSGN
$378M
| $128K | 0.01% |
+12,523
| New | +$128K |
|
320
Mersana Therapeutics
MRSN
$38.2M
| $128K | 0.01% |
874
+286
| +49% | +$41.9K |
|
321
ImmunityBio
IBRX
$2.43B
| $125K | 0.01% |
24,706
-3,098
| -11% | -$15.7K |
|
322
Karyopharm Therapeutics
KPTI
$54.9M
| $124K | 0.01% |
2,434
-628
| -21% | -$32K |
|
323
PMV Pharmaceuticals
PMVP
$84.8M
| $121K | 0.01% |
13,884
-6,000
| -30% | -$52.3K |
|
324
Sangamo Therapeutics
SGMO
$157M
| $116K | 0.01% |
37,007
+9,284
| +33% | +$29.1K |
|
|
PNT
325
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $113K | 0.01% |
15,530
+5,318
| +52% | +$38.7K |
|